furafylline has been researched along with raltegravir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andréola, ML; Bailly, F; Calmels, C; Christ, F; Cotelle, P; Debyser, Z; Lion, C; Suchaud, V | 1 |
| Andréola, ML; Bailly, F; Billamboz, M; Christ, F; Cotelle, P; Debyser, Z; Lion, C; Suchaud, V | 1 |
2 other study(ies) available for furafylline and raltegravir
| Article | Year |
|---|---|
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
Topics: Aryl Hydrocarbon Hydroxylases; Cell Line, Tumor; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Resistance, Viral; HIV Integrase Inhibitors; HIV-1; Humans; Isoquinolines; Molecular Docking Simulation; Mutation; Structure-Activity Relationship | 2014 |
2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
Topics: Alkylation; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Integrase Inhibitors; Humans; Isoquinolines; Structure-Activity Relationship | 2016 |